NCT01788228View on ClinicalTrials.gov

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 22, 2013

Primary Completion Date

March 27, 2014

Study Completion Date

February 25, 2015

Conditions
InfluenzaInfluenza Vaccines
Interventions
BIOLOGICAL

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)

2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.

Trial Locations (3)

20850

GSK Investigational Site, Rockville

30281

GSK Investigational Site, Stockbridge

53715

GSK Investigational Site, Madison

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01788228 - Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure | Biotech Hunter | Biotech Hunter